GlobeNewswire Clinical StudiesOriginal article
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
Phase 2positiveRM-718Positive
AI Analysis
Summary
Rhythm Pharmaceuticals announced positive preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity, demonstrating an 11.6% mean BMI reduction at Week 16 in seven patients, with results consistent with comparator drugs setmelanotide and bivamelagon.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Patients
7
Outcome Details
-11.6% mean reduction in BMI from baseline at Week 16 (n=7)
Importance:7/10
Sentiment:
0.75
Phase 2obesityefficacyBMI reductionpreliminary data
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on August 4, 2026 10:55 AM